Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...

Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet ...

Shares of Merck & Co. Inc. MRK slipped 1.43% to $113.09 Thursday, on what proved to be an all-around favorable trading ...

Shares of Merck (NYSE:MRK) traded marginally higher on Friday after falling from a high of $119.38 from the past seven ...

Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the ...

We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...

India], September 30: Merck Foundation, the philanthropic arm of Merck KGaA Germany marks ‘World Heart Day 2024’ in ...

Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...

Merck & Co. has picked up options on two Evaxion vaccine candidates, paying $3.2 million and dangling more than $1 billion in ...

On Friday, Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $113.69 which represents a slight increase of $0.60 or 0.53% from the prior close of $113.09. The stock opened at $113.17 ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.